Catalano D, Valente A, Fucci G
Rofo. 1976 Sep;125(3):262-3. doi: 10.1055/s-0029-1230458.
In vivo and in vitro studies have been performed in a group of patients with immunoproliferative diseases to evaluate the risk of serious reactions due to serum jelling after intravenous injection of iodinated contrast media. Sol-jell convertion and/or turbidimetric variations have not been observed when either sera or plasmas have been mixed with variable amounts of a methylglucamine salt of ioglycamic acid (MGI) and other compounds. In addition, no side-effects have been clinically recorded in three patients with Waldenströms macroglobulinaemia (WM) whose sera and/or plasmas had been studied in vitro, when they have been submitted to intravenous contrast examinations. The results suggest that there is not an evidence of a relationship between iodinated contrast media and fatal reactions due to sol-jell alterations in patients with WM and therefore a radiological examination using contrast media may be carried out in those patients.
已对一组免疫增殖性疾病患者进行了体内和体外研究，以评估静脉注射碘化造影剂后血清胶凝导致严重反应的风险。当血清或血浆与不同量的碘甘氨酸甲基葡胺盐（MGI）和其他化合物混合时，未观察到溶胶-凝胶转化和/或比浊变化。此外，对3例血清和/或血浆已进行体外研究的华氏巨球蛋白血症（WM）患者进行静脉造影检查时，临床上未记录到副作用。结果表明，没有证据表明碘化造影剂与WM患者因溶胶-凝胶改变导致的致命反应之间存在关联，因此这些患者可以进行使用造影剂的放射学检查。
